A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.

Antibodies, Monoclonal / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bevacizumab / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy Humans Lung Neoplasms / drug therapy Quality of Life
Lung cancer Monoclonal antibodies Non-small cell Targeted treatment

Journal

Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103

Informations de publication

Date de publication:
2021
Historique:
entrez: 16 3 2021
pubmed: 17 3 2021
medline: 19 3 2021
Statut: ppublish

Résumé

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer worldwide. It metastasizes rapidly and has a poor prognosis. The first-line treatment for most patients is a combination of chemotherapy and radiation. In many subjects, using targeted treatments alongside chemoradiation has shown a better outcome in terms of progression and quality of life for patients. These targeted treatments include small biological inhibiting molecules and monoclonal antibodies. In this review, we have assessed studies focused upon the treatment of non-small cell lung cancer. Some therapies are approved, such as bevacizumab and atezolizumab, while some are still in clinical trials, such as ficlatuzumab and ipilimumab, and others have been rejected due to inadequate disease control, such as figitumumab.

Identifiants

DOI: 10.1007/978-3-030-55035-6_3 PMID: 33725344
pubmed: 33725344
doi: 10.1007/978-3-030-55035-6_3
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antineoplastic Agents, Immunological 0
Bevacizumab 2S9ZZM9Q9V

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-64

Références

Moya-Horno I, Viteri S, Karachaliou N, Rosell R (2018) Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol 10:1758834017745012. https://doi.org/10.1177/1758834017745012
doi: 10.1177/1758834017745012 pubmed: 29383034 pmcid: 5784559
Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E et al (2017) Second-line treatment options in non-small-cell lung cancer: report from an international experts panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 19(4):301–314
pubmed: 29396237 doi: 10.1016/j.cllc.2017.12.010 pmcid: 29396237
Silva AP, Coelho PV, Anazetti M, Simioni PU (2017) Targeted therapies for the treatment of non-small-cell lung cancer: monoclonal antibodies and biological inhibitors. Hum Vaccin Immunother 13(4):843–853
pubmed: 27831000 doi: 10.1080/21645515.2016.1249551 pmcid: 27831000
Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA et al (2017) Current and emergent therapy options for advanced squamous-cell lung cancer. J Thorac Oncol 13(2):165–183
pubmed: 29175116 doi: 10.1016/j.jtho.2017.11.111 pmcid: 29175116
Vestergaard HH, Christensen MR, Lassen UN (2018) A systematic review of targeted agents for non-small cell lung cancer. Acta Oncol 57(2):176–186
pubmed: 29172833 doi: 10.1080/0284186X.2017.1404634 pmcid: 29172833
Johnson DB, Rioth MJ, Horn L (2014) Immune checkpoint inhibitors in NSCLC. Curr Treat Options in Oncol 15(4):658–669
doi: 10.1007/s11864-014-0305-5
Pirker R (2013) EGFR-directed monoclonal antibodies in non-small cell lung cancer. Target Oncol 8(1):47–53
pubmed: 23300028 doi: 10.1007/s11523-012-0244-7 pmcid: 23300028
Evans M, O’Sullivan B, Smith M, Hughes F, Mullis T, Trim N et al (2018) Large-scale EGFR mutation testing in clinical practice: analysis of a series of 18,920 non-small cell lung cancer cases. Pathol Oncol Res 25(4):1401–1409
pubmed: 30094734 doi: 10.1007/s12253-018-0460-2 pmcid: 30094734
Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4(7):397–406
pubmed: 12850190 doi: 10.1016/S1470-2045(03)01137-9 pmcid: 12850190
Pirker R, Filipits M (2011) Monoclonal antibodies against EGFR in non-small cell lung cancer. Crit Rev Oncol/Hematol 80(1):1–9
doi: 10.1016/j.critrevonc.2010.10.008
Pirker R, Pereira JR, Szczesna A, Von Pawel J, Krzakowski M, Ramlau R et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525–1531
pubmed: 19410716 doi: 10.1016/S0140-6736(09)60569-9 pmcid: 19410716
Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Robert H et al (2007) B3-03: a randomized multicenter phase III study of cetuximab (Erbitux
doi: 10.1097/01.JTO.0000283155.03863.e7
da Cunha SG, Shepherd FA, Tsao MS (2011) EGFR mutations and lung cancer. Annu Rev Pathol 6:49–69
doi: 10.1146/annurev-pathol-011110-130206
Wood DE (2015) National Comprehensive Cancer Network (NCCN) clinical practice guidelines for lung cancer screening. Thorac Surg Clin 25(2):185–197
pubmed: 25901562 doi: 10.1016/j.thorsurg.2014.12.003 pmcid: 25901562
Masters GA, Johnson DH, Temin S (2016) Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 12(1):90–93
pubmed: 29424582 doi: 10.1200/JOP.2015.008524 pmcid: 29424582
Mazzarella L, Guida A, Curigliano G (2018) Cetuximab for treating non-small cell lung cancer. Expert Opin Biol Ther 18(4):483–493
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199
pubmed: 25601342 pmcid: 25601342 doi: 10.1016/S1470-2045(14)71207-0
Solomon MT, Miranda N, Jorrín E, Chon I, Marinello JJ, Alert J et al (2014) Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience. Cancer Biol Ther 15(5):504–509
pubmed: 24521695 pmcid: 4026072 doi: 10.4161/cbt.28021
Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I et al (2017) A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). Oncotarget 8(9):15943–15951
pubmed: 27823977 doi: 10.18632/oncotarget.13056 pmcid: 27823977
Lee JY, Sun JM, Lim SH, Kim HS, Yoo KH, Jung KS et al (2015) A phase Ib/II study of afatinib in combination with nimotuzumab in non–small cell lung cancer patients with acquired resistance to gefitinib or erlotinib. Clin Cancer Res 22(9):2139–2145
pubmed: 26667485 doi: 10.1158/1078-0432.CCR-15-1653 pmcid: 26667485
Qi D, Cui Y, Wang Q, Huang C, Xu J, Yang Y et al (2015) A clinical trial on docetaxel and carboplatin therapy with or without nimotuzumab for the treatment of advanced nonsmall cell lung cancer. J Cancer Res Ther 11(Suppl 1):C32–C37. https://doi.org/10.4103/0973-1482.163836
doi: 10.4103/0973-1482.163836 pubmed: 26323921 pmcid: 26323921
Kim SH, Shim HS, Cho J, Jeong JH, Kim SM, Hong YK et al (2013) A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 79(3):270–275
pubmed: 23261229 doi: 10.1016/j.lungcan.2012.11.017 pmcid: 23261229
Bebb G, Smith C, Rorke S, Boland W, Nicacio L, Sukhoo R et al (2011) Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 67(4):837–845
pubmed: 20563810 doi: 10.1007/s00280-010-1379-9 pmcid: 20563810
Choi HJ, Sohn JH, Lee CG, Shim HS, Lee IJ, Yang WI et al (2011) A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 71(1):55–59
pubmed: 20451284 doi: 10.1016/j.lungcan.2010.04.010 pmcid: 20451284
Sung H-J, Cho J-Y (2008) Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41(9):615–625
pubmed: 18823584 doi: 10.5483/BMBRep.2008.41.9.615 pmcid: 18823584
Molina R, Filella X, Auge J, Fuentes R, Bover I, Rifa J et al (2003) Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Tumor Biol 24(4):209–218
doi: 10.1159/000074432
Hartmann J, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm M, Heeger S et al (2013) A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. Investig New Drugs 31(3):661–668
doi: 10.1007/s10637-012-9856-0
Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K et al (2006) A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 17(6):1007–1013
pubmed: 16533873 doi: 10.1093/annonc/mdl042 pmcid: 16533873
Schiller JH, von Pawel J, Schütt P, Ansari RH, Thomas M, Saleh M et al (2010) Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 5(12):1977–1985
pubmed: 20978446 doi: 10.1097/JTO.0b013e3181f4a5c9 pmcid: 20978446
Chigutsa E, Long AJ, Wallin JE (2017) Exposure-response analysis of necitumumab efficacy in squamous non-small cell lung cancer patients. CPT Pharmacometrics Syst Pharmacol 6(8):560–568
pubmed: 28569042 pmcid: 5572351 doi: 10.1002/psp4.12209
Thakur MK, Wozniak AJ (2017) Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma. Lung Cancer 8:13–19
pubmed: 28293124 pmcid: 28293124
Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16(7):763–774
pubmed: 26045340 doi: 10.1016/S1470-2045(15)00021-2 pmcid: 26045340
Paz-Ares L, Socinski M, Shahidi J, Hozak R, Soldatenkova V, Kurek R et al (2016) Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol 27(8):1573–1579
pubmed: 27207107 pmcid: 4959928 doi: 10.1093/annonc/mdw214
Reck M, Socinski MA, Luft A, Szczęsna A, Dediu M, Ramlau R et al (2016) The effect of necitumumab in combination with gemcitabine plus cisplatin on tolerability and on quality of life: results from the phase 3 SQUIRE trial. J Thorac Oncol 11(6):808–818
pubmed: 26980471 doi: 10.1016/j.jtho.2016.03.002 pmcid: 26980471
Reck M, Thomas M, Kropf-Sanchen C, Mezger J, Socinski MA, Depenbrock H et al (2016) Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR-expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE). Oncol Res Treat 39(9):539–547
pubmed: 27614872 doi: 10.1159/000448085 pmcid: 27614872
Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK et al (2017) Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in east Asian patients with stage IV squamous non-small cell lung cancer: a subgroup analysis of the phase 3, open-label, randomized SQUIRE study. Cancer Res Treat 49(4):937–946
pubmed: 28111429 pmcid: 5654161 doi: 10.4143/crt.2016.423
Spigel DR, Luft A, Depenbrock H, Ramlau R, Khalil M, Kim JH et al (2017) An open-label, randomized, controlled phase II study of paclitaxel-carboplatin chemotherapy with necitumumab versus paclitaxel-carboplatin alone in first-line treatment of patients with stage IV squamous non–small-cell lung cancer. Clin Lung Cancer 18(5):480–488
pubmed: 28365238 doi: 10.1016/j.cllc.2017.02.002 pmcid: 28365238
Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M et al (2015) Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 16(3):328–337
pubmed: 25701171 doi: 10.1016/S1470-2045(15)70046-X
Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K et al (2008) US Food and Drug Administration approval: panitumumab for epidermal growth factor receptor–expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 14(5):1296–1302
pubmed: 18316547 doi: 10.1158/1078-0432.CCR-07-1354
Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH et al (2008) Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14(2):502–508
pubmed: 18223225 doi: 10.1158/1078-0432.CCR-07-1509 pmcid: 18223225
Crawford J, Swanson P, Schwarzenberger P, Sandler A, Prager D, Zhang K et al (2013) A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non–small-cell lung cancer. J Thorac Oncol 8(12):1510–1518
pubmed: 24389433 doi: 10.1097/JTO.0b013e3182a7d1da pmcid: 24389433
Schuette W, Behringer D, Stoehlmacher J, Kollmeier J, Schmager S, von Weikersthal LF et al (2015) CHAMP: a phase II study of panitumumab with pemetrexed and cisplatin versus pemetrexed and cisplatin in the treatment of patients with advanced-stage primary nonsquamous non–small-cell lung cancer with particular regard to the KRAS status. Clin Lung Cancer 16(6):447–456
pubmed: 26094080 doi: 10.1016/j.cllc.2015.05.009 pmcid: 26094080
Edelman MJ, Hu C, Le QT, Donington JS, D’Souza WD, Dicker AP et al (2017) Randomized phase II study of preoperative chemoradiotherapy±panitumumab followed by consolidation chemotherapy in potentially operable locally advanced (stage IIIa, N2+) non–small cell lung cancer: NRG oncology RTOG 0839. J Thorac Oncol 12(9):1413–1420
pubmed: 28629896 pmcid: 5594738 doi: 10.1016/j.jtho.2017.06.007
Spigel DR, Mekhail TM, Waterhouse D, Hadley T, Webb C, Burris HA III et al (2017) First-line carboplatin, pemetrexed, and panitumumab in patients with advanced non-squamous KRAS wild type (WT) non-small-cell lung cancer (NSCLC). Cancer Investig 35(8):541–546
doi: 10.1080/07357907.2017.1344698
Wang Y, Wang H, Jiang Y, Zhang Y, Wang X (2017) A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer. Biomed Pharmacother 89:875–879
pubmed: 28282789 doi: 10.1016/j.biopha.2017.02.097 pmcid: 28282789
Blumenschein GR, Reckamp K, Stephenson GJ, O’Rourke T, Gladish G, McGreivy J et al (2010) Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non–small cell lung cancer. Clin Cancer Res 16(1):279–290
pubmed: 20028752 doi: 10.1158/1078-0432.CCR-09-1675 pmcid: 20028752
Wieck MM, Spurrier RG, Levin DE, Mojica SG, Hiatt MJ, Reddy R et al (2016) Sequestration of vascular endothelial growth factor (VEGF) induces late restrictive lung disease. PLoS One 11(2):e0148323. https://doi.org/10.1371/journal.pone.0148323
doi: 10.1371/journal.pone.0148323 pubmed: 26863115 pmcid: 4749176
Niu G, Chen X (2010) Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 11(8):1000–1017
pubmed: 20426765 pmcid: 3617502 doi: 10.2174/138945010791591395
Chen XW, Sun JG, Zhang LP, Liao XY, Liao RX (2017) Recruitment of CD11b+ Ly6C+ monocytes in non-small cell lung cancer xenografts challenged by anti-VEGF antibody. Oncol Lett 14(1):615–622
pubmed: 28693213 pmcid: 5494733 doi: 10.3892/ol.2017.6236
Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2(12):1097–1105
pubmed: 22866201 pmcid: 3411125 doi: 10.1177/1947601911423031
Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin
pubmed: 17602060 doi: 10.1634/theoncologist.12-6-713 pmcid: 17602060
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. New Engl J Med 355(24):2542–2550
pubmed: 17167137 doi: 10.1056/NEJMoa061884
Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M et al (2009) Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non–small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 27(9):1405–1412
pubmed: 19224857 pmcid: 3527732 doi: 10.1200/JCO.2008.16.2412
von Pawel J, Spigel DR, Ervin T, Losonczy G, Barlesi F, Juhász E et al (2018) Randomized phase II trial of parsatuzumab (anti-EGFL7) or placebo in combination with carboplatin, paclitaxel, and bevacizumab for first-line nonsquamous non-small cell lung cancer. Oncologist 23(6):654–e58. https://doi.org/10.1634/theoncologist.2017-0690
doi: 10.1634/theoncologist.2017-0690
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665–673
pubmed: 24933332 doi: 10.1016/S0140-6736(14)60845-X pmcid: 24933332
Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D et al (2017) Outcomes in patients with aggressive or refractory disease from REVEL: a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer 112:181–187
pubmed: 29191593 doi: 10.1016/j.lungcan.2017.07.038 pmcid: 29191593
Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB et al (2018) Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemother Pharmacol 82(1):77–86
pubmed: 29721850 doi: 10.1007/s00280-018-3560-5 pmcid: 29721850
Gil-Bazo I (2017) Avelumab—a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer. Transl Lung Cancer Res 6(S1):S35–S38. https://doi.org/10.21037/tlcr.2017.11.01
doi: 10.21037/tlcr.2017.11.01 pubmed: 29299406 pmcid: 5750149
Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D et al (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2(9):846–856
pubmed: 24872026 doi: 10.1158/2326-6066.CIR-14-0040 pmcid: 24872026
Cui S, Dong L, Qian J, Ye L, Jiang L (2018) Classifying non-small cell lung cancer by status of programmed cell death ligand 1 and tumor-infiltrating lymphocytes on tumor cells. J Cancer 9(1):129–134
pubmed: 29290777 pmcid: 5743719 doi: 10.7150/jca.21842
Santini FC, Rudin CM (2017) Atezolizumab for the treatment of non-small cell lung cancer. Expert Rev Clin Pharmacol 10(9):935–945
pubmed: 28714780 pmcid: 6089509 doi: 10.1080/17512433.2017.1356717
Passiglia F, Galvano A, Rizzo S, Incorvaia L, Listì A, Bazan V et al (2018) Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: an indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer 142(6):1277–1284
pubmed: 29080213 doi: 10.1002/ijc.31136
Bianco A, Malapelle U, Rocco D, Perrotta F, Mazzarella G (2018) Targeting immune checkpoints in non small cell lung cancer. Curr Opin Pharm 40:46–50
doi: 10.1016/j.coph.2018.02.006
Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550
pubmed: 26712084 doi: 10.1016/S0140-6736(15)01281-7 pmcid: 26712084
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17(11):1497–1508
pubmed: 27745820 pmcid: 6886237 doi: 10.1016/S1470-2045(16)30498-3
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. New Engl J Med 375(19):1823–1833
pubmed: 27718847 doi: 10.1056/NEJMoa1606774 pmcid: 27718847
Seetharamu N, Preeshagul IR, Sullivan KM (2017) New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab. Lung Cancer 8:67–78
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18(1):31–41
pubmed: 27932067 doi: 10.1016/S1470-2045(16)30624-6 pmcid: 27932067
Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B et al (2017) Nivolumab exposure–response analyses of efficacy and safety in previously treated squamous or nonsquamous non–small cell lung cancer. Clin Cancer Res 23(18):5394–5405
pubmed: 28916617 doi: 10.1158/1078-0432.CCR-16-2842 pmcid: 28916617
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373(17):1627–1639
pubmed: 26412456 pmcid: 5705936 doi: 10.1056/NEJMoa1507643
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 373(2):123–135
pubmed: 26028407 pmcid: 4681400 doi: 10.1056/NEJMoa1504627
Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ et al (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 7(1). https://doi.org/10.1038/s41598-017-06002-8
Ilie M, Hofman P (2017) Atezolizumab in advanced non-small cell lung cancer. J Thorac Dis 9(10):3603–3606
pubmed: 29268352 pmcid: 5723868 doi: 10.21037/jtd.2017.09.73
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265. https://doi.org/10.1016/S0140-6736(16)32517-X
doi: 10.1016/S0140-6736(16)32517-X pubmed: 27979383 pmcid: 27979383
Vansteenkiste J, Wauters E, Park K, Rittmeyer A, Sandler A, Spira A (2017) Prospects and progress of atezolizumab in non-small cell lung cancer. Expert Opin Biol Ther 17(6):781–789
pubmed: 28335643 doi: 10.1080/14712598.2017.1309389 pmcid: 28335643
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 377(20):1919–1929
pubmed: 28885881 pmcid: 28885881 doi: 10.1056/NEJMoa1709937
Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M et al (2016) A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study. Clin Lung Cancer 17(3):232–236. e231
pubmed: 27265743 doi: 10.1016/j.cllc.2016.03.003 pmcid: 27265743
Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A et al (2016) Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PD-L1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer. Lancet Oncol 17(3):299–308
pubmed: 26858122 pmcid: 5500167 doi: 10.1016/S1470-2045(15)00544-6
Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X et al (2016) Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol 11(1):95. https://doi.org/10.1186/s13000-016-0545-8
doi: 10.1186/s13000-016-0545-8 pubmed: 27717372 pmcid: 5055695
Shafique MR, Robinson LA, Antonia S (2018) Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Manag Res 10:931–940
pubmed: 29760563 pmcid: 5937504 doi: 10.2147/CMAR.S148009
Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJ et al (2017) Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN solid tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 18(5):599–610
pubmed: 28373005 pmcid: 5522719 doi: 10.1016/S1470-2045(17)30240-1
Xie H, Adjei AA (2017) Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. Transl Lung Cancer Res 6(Suppl 1):S41–S43. https://doi.org/10.21037/tlcr.2017.10.15
doi: 10.21037/tlcr.2017.10.15 pubmed: 29299408 pmcid: 5750158
Xu Y, Kong GKW, Menting JG, Margetts MB, Delaine CA, Jenkin LM et al (2018) How ligand binds to the type 1 insulin-like growth factor receptor. Nat Commun 9(1):821. https://doi.org/10.1038/s41467-018-03219-7
doi: 10.1038/s41467-018-03219-7 pubmed: 29483580 pmcid: 5826941
Yuan J, Yin Z, Tao K, Wang G, Gao J (2018) Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy. Oncol Lett 15(1):41–47
pubmed: 29285186 pmcid: 29285186
Humar M, Kern I, Vlacic G, Hadzic V, Cufer T (2017) Insulin-like growth factor 1 receptor expression in advanced non-small-cell lung cancer and its impact on overall survival. Radiol Oncol 51(2):195–202
pubmed: 28740455 pmcid: 5514660 doi: 10.1515/raon-2017-0020
Scagliotti G, Bondarenko I, Blackhall F, Barlesi F, Hsia TC, Jassem J et al (2014) Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol 26(3):497–504
pubmed: 25395283 doi: 10.1093/annonc/mdu517 pmcid: 25395283
Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T (2014) Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non–small-cell lung cancer. J Clin Oncol 32(19):2059–2066
pubmed: 24888810 pmcid: 4067944 doi: 10.1200/JCO.2013.54.4932
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D et al (2009) Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 4(11):1397–1403
pubmed: 19745765 pmcid: 2941876 doi: 10.1097/JTO.0b013e3181ba2f1d
Nakagawa T, Ohta K, Kubozono K, Ishida Y, Naruse T, Takechi M et al (2015) Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2. Arch Oral Biol 60(4):557–565
pubmed: 25601046 doi: 10.1016/j.archoralbio.2014.09.012 pmcid: 25601046
de Oliveira CC, Brizeno LAC, de Sousa FB, Mota MRL, Alves APNN (2016) Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - review. Med Oral Patol Oral Cir Bucal 21(4):e431–e439. https://doi.org/10.4317/medoral.21044
doi: 10.4317/medoral.21044 pubmed: 26827069 pmcid: 4920456
Panagiotidis I, Christoulas D, Terpos E (2016) Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma. Ann Transl Med 4(24):510. https://doi.org/10.21037/atm.2016.11.75
doi: 10.21037/atm.2016.11.75 pubmed: 28149872 pmcid: 5233538
Narducci P, Bareggi R, Nicolin V (2011) Receptor activator for nuclear factor kappa B ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology. Acta Histochem 113(2):73–81
pubmed: 19926120 doi: 10.1016/j.acthis.2009.10.003 pmcid: 19926120
Udagawa H, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K et al (2017) Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases. J Cancer Res Clin Oncol 143(6):1075–1082
pubmed: 28220258 doi: 10.1007/s00432-017-2350-5 pmcid: 28220258
Hendriks LE, Hermans BC, van den Beuken-van MH, Hochstenbag MM, Dingemans A-MC (2016) Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non–small cell lung Cancer and bone metastases: a systematic review. J Thorac Oncol 11(2):155–173
pubmed: 26718881 doi: 10.1016/j.jtho.2015.10.001 pmcid: 26718881
Curioni-Fontecedro A, Husmann L, Soldini D, Stahel R (2013) Primary non-small cell lung cancer response upon treatment with denosumab. Lung Cancer 82(3):506–508
pubmed: 24075124 doi: 10.1016/j.lungcan.2013.08.030 pmcid: 24075124
Takeno A, Yamamoto M, Notsu M, Sugimoto T (2016) Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report. BMC Endo Dis 16(1):66. https://doi.org/10.1186/s12902-016-0148-0
doi: 10.1186/s12902-016-0148-0
Yassin M, Soliman A, De Sanctis V, Abdelrahman M, Aziz Bedair E, AbdelGawad M (2014) Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis. Indian J Endocrinol Metab 18(4):546–551
pubmed: 25143915 pmcid: 4138914 doi: 10.4103/2230-8210.137516
Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC et al (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123(15):2936–2944. https://doi.org/10.1002/cncr.30717
doi: 10.1002/cncr.30717 pubmed: 28472537 pmcid: 5517339
Bottaro DP, Rubin JS, Faletto DL, Chan AL, Kmiecik TE, Woude GV et al (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251(4995):802–804
pubmed: 1846706 doi: 10.1126/science.1846706 pmcid: 1846706
Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C et al (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 10(10):2867–2878
pubmed: 1655405 pmcid: 452997 doi: 10.1002/j.1460-2075.1991.tb07836.x
D’Arcangelo M, Cappuzzo F (2013) Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. Biologics 7:61–68
pubmed: 23493885 pmcid: 3593708
Mok TSK, Geater SL, Su WC, Tan EH, Yang JCH, Chang GC et al (2016) A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in Asian patients with advanced stage pulmonary adenocarcinoma. J Thorac Oncol 11(10):1736–1744
pubmed: 27448761 doi: 10.1016/j.jtho.2016.05.038 pmcid: 27448761
Thompson CB, Allison JP (1997) The emerging role of CTLA-4 as an immune attenuator. Immunity 7(4):445–450
pubmed: 9354465 doi: 10.1016/S1074-7613(00)80366-0 pmcid: 9354465
Rowshanravan B, Halliday N, Sansom DM (2017) CTLA-4: a moving target in immunotherapy. Blood 131(1):58–67
pubmed: 29118008 pmcid: 6317697 doi: 10.1182/blood-2017-06-741033
Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734–1736
pubmed: 8596936 doi: 10.1126/science.271.5256.1734 pmcid: 8596936
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R et al (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30(17):2046–2054
pubmed: 22547592 doi: 10.1200/JCO.2011.38.4032 pmcid: 22547592
Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R et al (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24(1):75–83
pubmed: 22858559 doi: 10.1093/annonc/mds213 pmcid: 22858559
Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D et al (2016) Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J Thorac Oncol 11(9):1511–1521
pubmed: 27296105 pmcid: 5063510 doi: 10.1016/j.jtho.2016.05.028
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP et al (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17(7):883–895
pubmed: 27269741 doi: 10.1016/S1470-2045(16)30098-5 pmcid: 27269741
Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W et al (2016) Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 34(31):3740–3748
pubmed: 27458307 doi: 10.1200/JCO.2016.67.6601 pmcid: 27458307
Planchard D, Barlesi F, Gomez-Roca C, Mazieres J, Varga A, Greillier L et al (2016) Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM). Ann Oncol 27(Suppl 6):vi429. https://doi.org/10.1093/annonc/mdw383.45
doi: 10.1093/annonc/mdw383.45
Tabernero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS et al (2015) Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol 10(1):65–76
pubmed: 24816908 doi: 10.1007/s11523-014-0315-z pmcid: 24816908
Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L et al (2010) A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 16(23):5883–5891
pubmed: 20947515 doi: 10.1158/1078-0432.CCR-10-0631 pmcid: 20947515
Paz-Ares L, Bálint B, de Boer RH, van Meerbeeck JP, Wierzbicki R, De Souza P et al (2013) A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non–small-cell lung Cancer. J Thorac Oncol 8(3):329–337
pubmed: 23370314 doi: 10.1097/JTO.0b013e31827ce554 pmcid: 23370314

Auteurs

Yunes Panahi (Y)

Pharmacotherapy Department, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Amir Hossein Mohammadzadeh (AH)

Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Behzad Behnam (B)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Herbal and Traditional Medicines Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Kerman University of Medical Sciences, Kerman, Iran.

Hossein M Orafai (HM)

Faculty of Pharmacy, Department of Pharmaceutics, University of Ahl Al Bayt, Karbala, Iraq.
Faculty of Pharmacy, Department of Pharmaceutics, Al-Zahraa University, Karbala, Iraq.

Tannaz Jamialahmadi (T)

Department of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran.
Faculty of Medicine, Department of Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.

Amirhossein Sahebkar (A)

Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. amir_saheb2000@yahoo.com.
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. amir_saheb2000@yahoo.com.
Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. amir_saheb2000@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › A Review of Monoclonal Antibody-Based...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › A Review of Monoclonal Antibody-Based...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › A Review of Monoclonal Antibody-Based...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Bévacizumab › A Review of Monoclonal Antibody-Based...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › A Review of Monoclonal Antibody-Based...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A Review of Monoclonal Antibody-Based...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › A Review of Monoclonal Antibody-Based...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › A Review of Monoclonal Antibody-Based...